Gossamer Bio, Inc. (FRA:4GB)

Market Cap	444.18M +118.1%
Revenue (ttm)	37.54M -58.2%
Net Income	-133.10M
EPS	-0.59
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,349
Average Volume	2,346
Open	2.224
Previous Close	2.448
Day's Range	2.118 - 2.348
52-Week Range	0.648 - 3.174
Beta	n/a
RSI	39.99
Earnings Date	Mar 9, 2026

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The compa...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 145
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4GB

Financial Performance

Financial numbers in USD